Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence?
Ligation of the jugular veins does not result in brain inflammation or demyelination in mice.
Cost-effectiveness of early initiation of fingolimod versus delayed initiation after 1 year of intramuscular interferon Beta-1a in patients with multiple sclerosis.
Recommendations for the management of multiple sclerosis relapses.
MAIT cells in autoimmunity.
Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process.
Use of Intravenous Immunoglobulin in the Treatment of Immune-Mediated Demyelinating Diseases of the Nervous System.
Novel Δ(9) -tetrahydrocannabinol formulation Namisol® has beneficial pharmacokinetics and promising pharmacodynamic effects.
Genome-wide pathway analysis of a genome-wide association study on multiple sclerosis.
AMP-Activated Protein Kinase Restricts IFN-γ Signaling.
Neuromuscular taping in multiple sclerosis. A pilot study.
New TYSABRI® data show earlier treatment and longer-term use result in significant reductions in MS disease activity
Nearly one-half of Brazilian patients with multiple sclerosis using natalizumab are DNA-JC virus positive.
Extensive molluscum contagiosum virus infection in a young adult receiving fingolimod.
The Brd4 acetyllysine-binding protein is involved in activation of polyomavirus JC.
In situ expansion of T cells that recognize distinct self-antigens sustains autoimmunity in the CNS.
Tumor-like multiple sclerosis.
Relationship between Sustained Disability Progression and Functional System Scores in Relapsing-Remitting Multiple Sclerosis: Analysis of Placebo Data from Four Randomized Clinical Trials.
Multiple sclerosis: summary of NICE guidance.
Subcutaneous interferon β-1a in pediatric patients with multiple sclerosis: Regional differences in clinical features, disease management, and treatment outcomes in an international retrospective study.
Association of SNPs rs6498169 and rs10984447 with multiple sclerosis in Saudi Patients: a model of the usefulness of familial aggregates in identifying genetic linkage in a multifactorial disease.
The geometric and spatial constraints of the microenvironment induce oligodendrocyte differentiation.
Abstracts of ECTRIMS (Congress of the European Committee for Treatment and Research in Multiple Sclerosis) 2013. October 2-5, 2013. Copenhagen, Denmark.
Severe auto-immune hemolytic anemia in a fingolimod-treated multiple sclerosis patient.
Modeling the variability in brain morphology and lesion distribution in multiple sclerosis by deep learning.
Pages
« first
‹ previous
…
143
144
145
146
147
148
149
150
151
…
next ›
last »